Wolfgang Miesbach on Insights from Guy Young’s ASH2025 Session on Next-Generation Gene Therapy
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn:
”The Immunogenicity Challenge in Next-Generation Gene Therapy Dr. Guy Young‘s ASH2025 session “Deconstructing Gene Therapy in Haemophilia” highlighted a critical tension: the ASC618 Phase 1/2 trial shows both patients of the first cohort dosed with 2e12 vg/kg developed high-titer inhibitors to the ET3 transgene.
What is ASC618?
ASC618 uses ET3—a bioengineered BDD-FVIII chimera incorporating porcine sequences (A1/A3 domains) designed to enhance secretion 10–100x over native human FVIII, enabling lower doses.
The Problem:
These porcine residues could have acted as potent neo-antigens, breaking tolerance even in previously naive patients.
Both are now on emicizumab.
Predictive immunogenicity modeling for non-native constructs needs strengthening before clinical translation.”
All from ASH25 featured in Hemostasis Today.
-
Mar 16, 2026, 17:12Cold-Stored vs Room-Temperature Platelets in Trauma-Induced Coagulopathy – JTH
-
Mar 16, 2026, 17:10Arturo Cesaro: First Meta-Analysis on the Vascular Protective Role of Semaglutide in PAD
-
Mar 16, 2026, 17:01Jeff Sternlicht: The Most Powerful Time to Lower Cholesterol Is Before Anyone Thinks You Need It
-
Mar 16, 2026, 16:14Siobhan Calafiore: Clinical Advantages of Apixaban Over Rivaroxaban in Reducing Bleeding Risk
-
Mar 16, 2026, 16:12Nuha El Sayed: Focused Summary of the 2026 ACC/AHA Guideline on Management of Dyslipidemia in Diabetes
-
Mar 16, 2026, 16:08Deepak Sudheendra: When a Vascular Looking Skin Pattern Isn’t Vascular
-
Mar 16, 2026, 16:06Surendra Karki։ Examining Blood Type and Coronary Heart Disease Risk in Australian Donors
-
Mar 16, 2026, 15:58Alan Nurden: Genome-Wide Analyses Unravel the Genetic Architecture of Coagulation and Fibrinolysis
-
Mar 16, 2026, 15:56Emmanuel J. Favaloro: Latest Publication from Sydney Centres on Heparin Therapy and Monitoring